Tivicay — Class III drug recall D-1185-2014
Terminated recall by Viiv Healthcare Company, reported 2014-04-09, distributed nationwide. Cross Contamination with Other Products: Product contains Promacta (eltrombopag).
| Recall number | D-1185-2014 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Viiv Healthcare Company, Durham, NC, United States |
| Recall initiated | 2014-02-11 |
| Classified | 2014-04-01 |
| Reported by FDA | 2014-04-09 |
| Terminated | 2014-08-21 |
| Distributed | Nationwide (US) |
| Quantity | 1,056 bottles |
| NDC | 49702-0226, 49702-0226-13, 49702-0227, 49702-0227-13, 49702-0228, 49702-0228-13, 49702-0255, 49702-0255-37 |
| Lot numbers | 10/15, 3ZP2210 |
Product
Tivicay (dolutegravir) Tablets 50 mg, 30 Tablet Bottles, Rx Only. Manufactured for: ViiV Health, TRP, NC 27709; by: GlaxoSmithKline, Research Triangle Park, NC 27709. Made in Japan. NDC 49702-228-13
Reason for recall
Cross Contamination with Other Products: Product contains Promacta (eltrombopag).
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1185-2014. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.